CERO · Cero Therapeutics Holdings, Inc. · Executive Compensation
$0.07
-0.02 (-25.26%)
At close · Oct 31
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$716,309
Shares
71.63M
Volume · Oct 31
7.27M
Avg daily vol (3M)
2.14M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brian G. Atwood | Former Chief Executive Officer | $1,806,508 |
| Daniel Corey | Former Chief Technology Officer and Former Chief Executive Officer | $1,073,213 |
| Chris Ehrlich | Chief Executive Officer | $998,748 |
| Charles Carter | Former Chief Financial Officer Andrew “Al” Kucharchuk | $690,262 |
| Charles R. Carter | Former Chief Financial Officer Andrew “Al” Kucharchuk | $690,262 |
| Kristen Pierce | Chief Development Officer | $119,777 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel Corey | Former Chief Technology Officer and Former Chief Executive Officer | $376,035 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel Corey | Chief Technology Officer and Former Chief Executive Officer | $372,685 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eric Francois | director | Appointed | 2026-02-13 |
| Andrew Albert Kucharchuk | Chief Financial Officer | Appointed | 2025-06-02 |
| Chris Ehrlich | Chief Executive Officer | Appointed | 2025-06-02 |
| Lindsey Rolfe, M.D. | Class I director | Appointed | 2025-05-29 |
| Michael Byrnes | Class I director | Appointed | 2025-05-29 |
| Chris Ehrlich | Chief Executive Officer | Appointed | 2024-12-06 |
| Shami Patel | Class III director | Appointed | 2024-10-11 |
| Kristen Pierce | Chief Development Officer | Appointed | 2024-10-02 |
| Andrew Albert "Al" Kucharchuk | Chief Financial Officer | Appointed | 2024-10-02 |
| Robyn Rapaport | Board | Resigned | 2024-10-02 |
| Chris Ehrlich | Interim Chairman and Chief Executive Officer | Appointed | 2024-10-02 |
| Brian G. Atwood | Chief Executive Officer | Resigned | 2024-10-02 |
| Andrew Albert "Al" Kucharchuk | Chief Financial Officer | Appointed | 2024-10-02 |
| Charles R. Carter | Chief Financial Officer | Resigned | 2024-10-02 |
| Daniel Corey | Chief Technology Officer | Resigned | 2024-09-25 |
| Daniel Corey | board seat | Resigned | 2024-09-25 |
| Charles Carter | Chief Financial Officer | Resigned | 2024-09-25 |
| Brian Atwood | President and CEO | Resigned | 2024-09-25 |
| Daniel Corey | director | Resigned | 2024-09-25 |
| Chris Ehrlich | Interim Chief Executive Officer | Appointed | 2024-09-25 |
| Daniel Corey | Chief Technology Officer | Resigned | 2024-09-25 |
| Chris Ehrlich | Interim Chairman | Appointed | 2024-09-25 |
| Brian G. Atwood | Chief Executive Officer | Resigned | 2024-09-25 |
| Robyn Rapaport | director | Appointed | 2024-02-15 |
| Michael Byrnes | director of the Company | Appointed | 2024-02-15 |